ClinicalTrials.gg
RecruitingNCT06373718SleepMOREUpdated Apr 20, 2026

Sleep Mechanisms Of Regulating Emotions

An interventional study of Cognitive Behavioral Therapy for Insomnia in Insomnia and Depression, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University — 2 open to participants now, 2 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Stanford University.

Planned enrollment
7th of 22
120 · median 68
Started
2024
the only one that year
No phase
16 of 22
2 open now
Registered
21st of 22
by date

Among the 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 16 with no phase, and was the 21st registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

2 of the 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University, or all of them as a file.
02

Study summary

This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target.

Read the detailed description

Several lines of evidence suggest that insomnia contributes to emotionally distressing depressive mood symptoms through disruption of brain networks that regulate emotional functions. Of particular concern, insomnia is associated with an increased risk for suicide, even when accounting for the presence of other depressive symptoms. However, it is not yet know to what degree that the emotion regulation brain network is modified by the restoration of sleep, or whether the degree to which a sleep intervention engages these neural targets mediates reductions in depressive symptoms and suicidality.

This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target.

This project aims to extend the initial findings from the first phase (IRB-56961) to (1) confirm target engagement, defined as the treatment effect on increasing mPFC-amygdala connectivity, and/or decreasing amygdala reactivity during emotion reactivity and regulation paradigms, by testing the hypothesis that compared with a control condition, CBT-I participants will show significant change in the emotion regulation network targets that met the Go Criteria of the first phase in the direction of normalization, at the end of treatment, (2) examine the relationships of target engagement to treatment outcomes by study group, and (3) test whether emotion regulation network measures at baseline predict depressive symptom and suicidality reduction.

Participants will be 120 adults experiencing at least moderate sleep disturbances and who also have elevated anxious and/or depressive symptoms. Eligible participants will be randomized into either the Immediate Treatment group, which will receive six sessions of CBT-I over the eight weeks of treatment phase immediately after randomization, or the Enhanced Sleep Hygiene group, which will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms and will be offered the same CBT-I as the Immediate Treatment group upon completion of the 6-month follow-up session, approximately 7 months after randomization. Emotion distress and sleep disruption will be assessed prior to, and weekly during the eight weeks of treatment phase. CBT-I improves sleep patterns through a combination of sleep restriction, stimulus control, mindfulness training, cognitive therapy targeting dysfunctional beliefs about sleep, and sleep hygiene education. Using fMRI scanning, emotion regulation network neural targets will be assayed prior to and following completion of CBT-I treatment.

03

Conditions studied

  • Insomnia
  • Depression

Keywords

  • Insomnia
  • Depression
  • Anxiety
  • CBT-I
  • Cognitive Behavioral Therapy for Insomnia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of any racial or ethnic group, aged 18-65
  • Subjective complaint of insomnia associated with daytime impairment or distress (ISI ≥ 10)
  • Insomnia complaint ≥ 3 months in duration
  • Subjective complaint of depressive symptoms as defined by scores of ≥ 14 on the BDI
  • Fluent and literate in English
  • Written,
  • Reside within 60 miles of Stanford University

Exclusion criteria

Exclusion Criteria:

  • Presence of other sleep or circadian rhythm disorders that significantly contribute to their sleep disturbance. The presence of these disorders will be assessed by the DUKE structured interview for sleep disorders
  • Use of psychotropic medications that would significantly impact sleep, alertness, or mood and unwilling or unable to discontinue medication specifically prescribed for sleep disturbance > two weeks (anti-depressants) or >1 week (sleep medications) prior to baseline data collection
  • Excessive alcohol consumption (>14 drinks per week or > 4 drinks per occasion)
  • Presence of suicidal ideations representing imminent risk as determined by the empirically-supported, standardized suicide risk assessment
  • General medical condition, disease or neurological disorder that interferes with the assessments
  • Substance abuse or dependence
  • History of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities OR traumatic brain injury in the past two months
  • Severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to complete the assessments, or are unable and/or unlikely to follow the study protocols
  • Pregnant or breast feeding
  • Current or lifetime history of bipolar disorder or psychosis
  • Current or expected cognitive behavior therapy or other evidence-based psychotherapies for another condition
  • Received cognitive behavioral therapy for insomnia within the past year
  • Acute or unstable chronic illness: including but not limited to: uncontrolled thyroid disease, kidney, prostate or bladder conditions causing excessively frequent urination (> 3 times per night); medically unstable congestive heart failure, angina, other severe cardiac illness as defined by treatment regimen changes in the prior 3 months; stroke with serious sequelae; cancer if \< 1 year since end of treatment; asthma, emphysema, or other severe respiratory diseases uncontrolled with medications; and neurological disorders such as Alzheimer's disease, Parkinson's disease and unstable epilepsy as defined by treatment regimen changes in the prior 3 months; unstable adult onset diabetes as defined by treatment regimen changes in the prior 3 months
  • Current exposure to trauma, or exposure to trauma within the past 3 months
  • Working a rotating shift that overlaps with 2400h
  • Individuals who were high risk for sleep apnea on the Berlin Questionnaire and are not CPAP adherent or have untreated OSA of moderate severity or worse (AHI ≥ 15)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Immediate Treatment

    Participants randomized to the Immediate Treatment group will receive CBT-I treatment immediately after randomization.

    Behavioral: Cognitive Behavioral Therapy for Insomnia

  • Other
    Enhanced Sleep Hygiene

    Participants randomized to the Enhanced Sleep Hygiene (ESH) group will be offered the same CBT-I described above approximately 7 months after being randomized. We will also provide a list of referrals for treatment upon completion of their end of treatment visit (approx. week 11) should they choose to seek treatment sooner. In the interim, they will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms.

    Behavioral: Cognitive Behavioral Therapy for Insomnia

Interventions

  • BehavioralCognitive Behavioral Therapy for Insomnia

    CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.

    Also known as: CBT-I

06

What researchers measure

Primary outcomes

  1. Change in Emotion Regulation Network brain activation as assessed by functional magnetic resonance imaging

    During functional magnetic resonance imaging the Emotion Regulation Network will be engaged by emotional tasks, and circuit activation will be quantified by blood flow in regions of interest.

    Time frame: Assessed at baseline (week 1) and end of treatment (week 13)

  2. Change in Emotion Regulation Network brain connectivity as assessed by functional magnetic resonance imaging

    During functional magnetic resonance imaging the Emotion Regulation Network will be engaged by emotional tasks, and circuit connectivity will be quantified by the correlation of the blood flow between regions of interest.

    Time frame: Assessed at baseline (week 1) and end of treatment (week 13)

  3. Change in Beck Depression Inventory

    This measure is of the Beck Depression Inventory-II total score after excluding one sleep item. The average item score for the remaining 20 items will be multiplied by 21 (the original number of items), to create a modified depression scale that maintains the original range (ranges: 0-13 minimal, 14-19 mild, 20-28 moderate, and 29-63 severe). The BDI-II is a 21-item self-report scale with high validity and reliability that assesses the severity of depression symptoms. The depression items consist of: sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, irritability, changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex. Items are scored from 0 to 3, and higher scores indicate greater levels of severity.

    Time frame: Assessed at baseline (week 1), throughout treatment phase (weeks 3-11), end of treatment (week 13), and 6-month follow-up (week 39)

  4. Change in PSG Sleep Efficiency

    Sleep efficiency (SE) is the percentage of total time in bed actually spent sleeping. Based on the overnight PSG sleep recording, SE will be calculated as the total time (minutes) spent asleep (sum of Stages N1, N2, N3, and REM) divided by the total time (minutes) in bed, and multiplied by 100.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  5. Change in Insomnia Severity Index (ISI) Scale Score

    Subjective ratings of sleep disturbance and insomnia severity will be assessed with the Insomnia Severity Index. The Insomnia Severity Index (ISI) is a 7-item self-report measure of insomnia type, severity, and impact on functioning. The items consist of severity of sleep onset, sleep maintenance, early morning awakenings, sleep dissatisfaction, interference with daytime functioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. Items are scored from 0 to 4 (0 = no problem, 4 = very severe problem). Score ranges of insomnia are: 0-7 absent, 8-14 sub-threshold, 15-21 moderate, and 22-28 severe. The ISI has good validity and reliability.

    Time frame: Assessed at baseline (week 1), throughout treatment phase (weeks 3-11), end of treatment (week 13), and 6-month follow-up (week 39)

Secondary outcomes

  1. Change in Columbia Suicide Severity Rating Scale

    The Columbia Suicide Severity Rating Scale is a 12-item checklist that was designed to quantify the severity of suicidal ideation and behavior. It is composed of two parts. The first six questions ask about suicidal ideation and behavior in the past month while the last six questions ask about suicidal ideation and behavior since the last visit. The CSSRS has been proven to be reliable and valid. It has also been shown to have high sensitivity and specificity to the different suicidal behavior classifications.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  2. Change in Actigraph Sleep Onset Latency (SOL) as a Measure of Sleep Continuity

    Sleep Onset Latency (SOL) is the time (minutes) from "lights out" to actually falling asleep (sleep onset).

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  3. Change in Actigraph Number of Arousals as a Measure of Sleep Continuity

    Number of Arousals is determined by number of times of awakening as seen on the actigraph data.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  4. Change in Actigraph Wake After Sleep Onset (WASO) as a Measure of Sleep Continuity

    Wake After Sleep Onset (WASO) are periods of wakefulness occurring after sleep onset, before final awakening (sleep offset).

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  5. Change in Actigraph Total Sleep Time (TST) as a Measure of Sleep Continuity

    Total Sleep Time (TST) is the total time spent asleep, from the start of sleep onset to sleep offset subtracting any periods of wakefulness.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  6. Change in Actigraph Sleep Efficiency (SE) as a Measure of Sleep Continuity

    Sleep Efficiency (SE) is calculated as TST divided by total time spent in bed, multiplied by 100.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  7. Change in PSG Sleep Onset Latency (SOL) as a Measure of Sleep Architecture

    Sleep Onset Latency (SOL) is the time (minutes) from "lights out" or start of total recording time, to actually falling asleep as indicated by EEG changes.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  8. Change in PSG Number of Arousals as a Measure of Sleep Architecture

    Number of Arousals is determined by number of times of awakening by EEG changes.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  9. Change in PSG Wake After Sleep Onset (WASO) as a Measure of Sleep Architecture

    Wake After Sleep Onset (WASO) are periods of wakefulness occurring after sleep onset, before final awakening (sleep offset) measured by EEG changes.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  10. Change in PSG Total Sleep Time (TST) as a Measure of Sleep Architecture

    Total Sleep Time (TST) is the total time (minutes) spent asleep, from the start of sleep onset to sleep offset, subtracting any periods of wakefulness. TST includes stages N1, N2, N3, and REM sleep.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  11. Change in PSG Sleep Efficiency (SE) as a Measure of Sleep Architecture

    Sleep Efficiency (SE) is calculated as TST divided by total time spent in bed, multiplied by 100. Duration of non-rapid eye movement (NREM) sleep includes stages N1, N2, and N3, and is measured in minutes. The duration of sleep outside of those stages that is associated with specific EEG stages is REM sleep.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  12. Change in Sleep Physiology measured by PSG

    Topographical EEG power spectral density analysis associated with sleep stages will be calculated in the Delta (0.5-Hz), Theta (4-7Hz), Alpha (7-11Hz), Sigma (12-15Hz), Beta-1 (15-20Hz), Beta-2 (20-35Hz) and Gamma (35-45Hz) bands, according to published methods.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  13. Change in 36-Item Short Form Survey (SF-36) Score

    The SF-36 measures health-related quality of life based on eight domains: limitations in physical activities because of health problems, limitations in social activities because of physical or emotional problems, limitations in usual role activities because of physical health problems, bodily pain, general mental health (psychological distress and well-being), limitations in usual role activities because of emotional problems, vitality (energy and fatigue), and general health perceptions. Items are recoded then averaged together to create each scale. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  14. Change in Beck Anxiety Inventory

    The BAI is a 21-item self-report scale that assesses the severity of anxiety symptoms. Items are scored from 0 to 3 (0 = not at all, 3 = severe). Higher scores indicate greater levels of severity, and the ranges for anxiety levels are: 0-9 normal to minimal, 10-18 mild to moderate, 19-29 moderate to severe, and 30-63 severe. The BAI consists of two factors: somatic and cognitive.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

  15. Change in Respiratory Sinus Arrhythmia (RSA)- measured by PSG

    RSA is the phenomenon of an increased heart rate during inhalation and a decreased heart rate during exhalation. Since these fluctuations are controlled mainly by vagal influences on the heart, RSA serves as a reliable metric for measuring parasympathetic activity. RSA has been proven to be a reliable measure of emotion regulation and emotional responding in numerous studies.

    Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2027, 34 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 34 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 18, 2024
StartActual
Aug 12, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06373718
Responsible party
Andrea Goldstein-Piekarski (Assistant Professor, Stanford University) — Principal investigator
First posted
Apr 18, 2024
Start date
Aug 12, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Kaela Mandler
Contact
kaelam@stanford.edu
650-721-6089
Leah Harris
Contact
leahharr@stanford.edu
Andrea Goldstein, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion